HK Stock Market Move | MAOYAN ENT (01896) fell more than 6% "Demon Slayer" officially released today, with a total box office exceeding 1.1 billion.
Cat Eye Entertainment (01896) fell more than 6%, as of the time of writing, it dropped 6.36%, closing at HK$7.36, with a turnover of HK$77.3162 million.
MAOYAN ENT (01896) fell more than 6%, as of the time of writing, it dropped 6.36% to HK$7.36, with a turnover of HK$77.3162 million.
On the news front, the Japanese animated film "Demon Slayer: Infinity Train" introduced by Maoyan Film Industry and co-distributed by China Film Group officially landed in theaters on November 14th and will also be shown in IMAX theaters. According to Maoyan's professional data, the film "Demon Slayer: Infinity Train Chapter 1 Yaiba Seat Re-appear" has a Maoyan rating of 9.7, with a cumulative box office of over 1.10 billion by now.
According to recent research reports by Citigroup, they are observing positive catalysts for MAOYAN ENT in the next 30 days, with the main driving factor being the release of the major animated film "Demon Slayer" scheduled for November 14th, with Maoyan as its distributor. Citigroup expects "Demon Slayer" to become the top Japanese animated film in China and assumes a box office of 1 billion RMB, with expected profit contributions ranging from 108 million to 200 million RMB, compared to the adjusted net profit expectation for 2025 of 542 million RMB.
Related Articles

After experiencing a sevenfold rebound in stock prices, Deutsche Bank (DB.US) is about to announce a three-year plan focusing on "stronger profitability + cost control."

Sunflower Pharmaceutical Group (002737.SZ): Compound polyethylene glycol (3350) electrolyte powder obtained drug registration certificate.

HK Stock Market Move | At the close, PEGBIO CO-B (02565) rose more than 12%, and its core product, the peptide injection Weipenapeptide, was approved for listing.
After experiencing a sevenfold rebound in stock prices, Deutsche Bank (DB.US) is about to announce a three-year plan focusing on "stronger profitability + cost control."

Sunflower Pharmaceutical Group (002737.SZ): Compound polyethylene glycol (3350) electrolyte powder obtained drug registration certificate.

HK Stock Market Move | At the close, PEGBIO CO-B (02565) rose more than 12%, and its core product, the peptide injection Weipenapeptide, was approved for listing.

RECOMMEND

Energy Storage Industry Set To Ride the AI Tailwind; UBS: Global Demand May Surge 40% Next Year
13/11/2025

Double Eleven’s Cooling To A Historic Low? A Necessary Step Toward E‑commerce Maturity
13/11/2025

On The Eve of L3 Mass Commercialization: How Autonomous Driving Will Reconfigure a Trillion‑Yuan Service Market
13/11/2025


